TABLE 2.
Proportion of patients with residual hyperglycaemia (HbA1c ≥ 7.0%/FPG < 140 mg/dL) at baseline and week 30 according to T2D duration, BMI and HbA1c at baseline
| iGlarLixi | iGlar | |||||
|---|---|---|---|---|---|---|
| Baseline, n (%) | Week 30, n (%) | Baseline, n (%) | Week 30, n (%) | Proportion difference between treatments (95% CI) | P‐value | |
| T2D duration, y | ||||||
| ≥10 | 132 (66.3) | 47 (23.6) | 136 (63.6) | 112 (52.3) | 29.1 (20.5‐37.7) | <.0001 |
| <10 | 97 (58.1) | 40 (24.0) | 91 (60.7) | 60 (40.0) | 16.2 (6.4‐26.0) | .0015 |
| BMI, kg/m2 | ||||||
| ≥30 | 126 (57.8) | 50 (22.9) | 127 (60.5) | 95 (45.2) | 22.1 (13.6‐30.5) | <.0001 |
| <30 | 103 (69.6) | 37 (25.0) | 100 (64.5) | 77 (49.7) | 25.5 (15.4‐35.5) | <.0001 |
| HbA1c, % | ||||||
| ≥8.5 | 64 (61.0) | 34 (32.4) | 61 (57.0) | 64 (59.8) | 26.9 (14.3‐39.6) | <.0001 |
| <8.5 | 165 (63.2) | 53 (20.3) | 166 (64.3) | 108 (41.9) | 22.0 (14.5‐29.6) | <.0001 |
Abbreviations: BMI, body mass index; CI, confidence interval; iGlar, insulin glargine Gla‐100; iGlarLixi, fixed‐ratio combination of insulin glargine and lixisenatide; n, number of patients in each category; T2D, type 2 diabetes.